NCT03246958 - Nivolumab Plus Ipilimumab in Thyroid Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 3, 2017

Primary Completion Date

January 21, 2021

Study Completion Date

July 31, 2021

Conditions

Thyroid Cancer

Interventions

DRUG

Nivolumab

Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.

DRUG

Ipilimumab

Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.

Trial Locations (1)

Dana Farber Cancer Institute, Boston